Dual-vector gene therapy for hearing loss secures first FDA approval [0.03%]
美国食品药品监督管理局首次批准双载体基因疗法治疗听力损失
Asher Mullard
Asher Mullard
Asher Mullard
Asher Mullard
Congzhou Chen,Xue Wang,Wei Wei et al.
Congzhou Chen et al.
Sarah Crunkhorn
Sarah Crunkhorn
Sarah Crunkhorn
Sarah Crunkhorn
Sarah Crunkhorn
Sarah Crunkhorn
Sarah Crunkhorn
Sarah Crunkhorn
Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies [0.03%]
当代小分子激酶调节剂的设计：正构位点、变构位点和诱导结合位点策略
Joachim Rudolph,Klaus P Hoeflich,Arvin C Dar
Joachim Rudolph
Small-molecule kinase modulators are an expanding class of compounds with broad impact on biology and medicine. However, although currently 100 inhibitors are FDA approved, many disease-linked kinases remain intractable to conventional ther...
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond [0.03%]
乳腺癌治疗及其他领域中CDK抑制剂使用的演变格局
Erik S Knudsen,Agnieszka K Witkiewicz,Sheheryar Kabraji
Erik S Knudsen
Cyclin-dependent kinases (CDKs) are key regulators of cell-cycle progression and have long been recognized as attractive therapeutic targets in oncology. Inhibitors of CDK4 and CDK6 have transformed the treatment of patients with breast can...